Abstract:Abstract Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are clonal hematopoietic stem cell diseases arising from the bone marrow (BM), and approximately 30% of MDS eventually progress to AML, associated with increasingly aggressive neoplastic hematopoietic clones and poor survival. Dysregulated immune microenvironment has been recognized as a key pathogenic driver of MDS and AML, causing high rate of intramedullary apoptosis in lower-risk MDS to immunosuppression in higher-risk MDS and AML. Immune checkpoint molecules, including programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1), play important roles in oncogenesis by maintaining an immunosuppressive tumor microenvironment. Recently, both molecules have been examined in MDS and AML. Abnormal inflammatory signaling, genetic and/or epigenetic alterations, interactions between cells, and treatment of patients all have been involved in dysregulating PD-1/PD-L1 signaling in these two diseases. Furthermore, with the PD-1/PD-L1 pathway activated in immune microenvironment, the milieu of BM shift to immunosuppressive, contributing to a clonal evolution of blasts. Nevertheless, numerous preclinical studies have suggested a potential response of patients to PD-1/PD-L1 blocker. Current clinical trials employing these drugs in MDS and AML have reported mixed clinical responses. In this paper, we focus on the recent preclinical advances of the PD-1/PD-L1 signaling in MDS and AML, and available and ongoing outcomes of PD-1/PD-L1 inhibitor in patients. We also discuss the novel PD-1/PD-L1 blocker-based immunotherapeutic strategies and challenges, including identifying reliable biomarkers, determining settings, and exploring optimal combination therapies.

The opportunities and challenges of using PD-1/PD-L1 inhibitors for leukemia treatment

Progress of research on PD-1/PD-L1 in leukemia

Acute Myeloid Leukemia Cell-Intrinsic PD-1 Functions Promoting Leukemia Development by Recruiting SHP2

Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia

The opportunities and challenges in immunotherapy: Insights from the regulation of PD-L1 in cancer cells.

Strategies targeting PD-L1 expression and associated opportunities for cancer combination therapy

Emerging therapeutic frontiers in cancer: insights into posttranslational modifications of PD-1/PD-L1 and regulatory pathways

The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer

Recent progress, perspectives, and issues of engineered PD-L1 regulation nano-system to better cure tumor: A review

New horizons in the mechanisms and therapeutic strategies for PD-L1 protein degradation in cancer

Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges

The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers

Immune Landscape and Therapeutic Strategies: New Insights into PD-L1 in Tumors

PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations

PD-L1: From cancer immunotherapy to therapeutic implications in multiple disorders

Recent Findings in the Regulation of Programmed Death Ligand 1 Expression

The Role of PD-1 and PD-L1 in T-cell Immune Suppression in Patients with Hematological Malignancies

PD-1/PD-L1 pathway: current researches in cancer.

PD-1 regulation in immune homeostasis and immunotherapy

Extracellular and nuclear PD-L1 in modulating cancer immunotherapy

Regulation of PD-L1 expression in the tumor microenvironment